Advanced search
Publication Cover
Current Medical Research and Opinion Volume 38, 2022 - Issue 8
Submit an article Journal homepage
681
Views
4
CrossRef citations to date
0
Altmetric
Neurology

Patient characteristics and treatment utilization among patients with migraine initiating self-injectable calcitonin gene-related peptide monoclonal antibody and novel acute medication

Oralee J. VarnadoEli Lilly and Company, Indianapolis, IN, USACorrespondence[email protected]
,
Maggie HoytEli Lilly and Company, Indianapolis, IN, USA
,
Wenyu YeEli Lilly and Company, Indianapolis, IN, USA
&
Robert NicholsonEli Lilly and Company, Indianapolis, IN, USA
Pages 1451-1457 | Received 21 Dec 2021, Accepted 14 Jun 2022, Published online: 11 Jul 2022

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Oralee J Varnado, Tania Gulati, Anthony Wheeler & Margaret Hoyt. (2023) Treatment Patterns, Healthcare Resource Utilization, and Direct Costs Among Patients Initiating Concomitant Use of a Calcitonin Gene-Related Peptide Monoclonal Antibody (CGRP mAb) and Novel Acute Medication in the United States. Patient Preference and Adherence 17, pages 3449-3459.
Read now
Lanfranco Pellesi, Thien Phu Do & Anders Hougaard. Pharmacological management of migraine: current strategies and future directions. Expert Opinion on Pharmacotherapy 0:0, pages 1-11.
Read now

Articles from other publishers (2)

Seyran Naghdi, Martin Underwood, Jason Madan, Anna Brown, Callum Duncan, Manjit Matharu, Aiva Aksentyte, Natasha Davies, Sophie Rees, Andrew Cooklin, Amy Grove & Hema Mistry. (2023) Clinical effectiveness of pharmacological interventions for managing chronic migraine in adults: a systematic review and network meta-analysis. The Journal of Headache and Pain 24:1.
Crossref
Zifan Zhou, Robert Urman, Karminder Gill, Andrew S. Park, Fiston Vuvu, Leah B. Patel, Jingsong Lu, Rolin L. Wade, Lindsay Frerichs & Mark E. Bensink. (2023) Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway. The Journal of Headache and Pain 24:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.